Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results

May 9, 2012

BLUE BELL, Pa., May 9, 2012 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended March 31, 2012.

Total revenue was $1.7 million for the three months ended March 31, 2012, compared to $3.1 million for the same period in 2011. Total operating expenses were $5.9 million compared to $7.5 million. The net loss attributable to common stockholders was $8.3 million, or $0.06 per share, compared to $2.4 million, or $0.02 per share.

Revenue

The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company’s contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $1.5 million versus $2.7 million, respectively. This NIAID contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio’s development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses

Research and development expenses for Q1 2012 were $4.0 million compared to $4.4 million for Q1 2011. General and administrative expenses were $2.5 million versus $3.3 million, respectively.

Net Loss Attributable to Common Stockholders

The $5.9 million increase in net loss for the comparable periods resulted primarily from a significant (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company’s stock price, and decrease in grant revenue.

Capital Resources

As of March 31, 2012, cash and cash equivalents plus short-term investments in certificates of deposit, mutual funds, and municipal bonds were $25.0 million compared with $30.3 million as of December 31, 2011.

Based on management’s projections and analysis, the Company believes that cash and cash equivalents are sufficient to meet its planned working capital requirements into the third quarter of 2013.

Inovio’s balance sheet and statement of operations is provided below. Form 10-Q providing the complete 2012 first quarter financial report can be found at: http://ir.inovio.com/secfilings.

Corporate Update

Clinical Development

During the first quarter Inovio reported significant vaccine-specific T-cell responses from its HIV-001 open label, phase I study, which enrolled 12 adult HIV-positive volunteers to assess safety and levels of immune responses generated by Inovio’s PENNVAX®-B vaccine delivered with its CELLECTRA® electroporation device. The results affirmed best-in-class immune responses reported last year from Inovio’s HVTN-080 phase I study of PENNVAX-B in healthy volunteers.

Enrollment is ongoing in Inovio’s phase II clinical study of VGX-3100 for cervical dysplasia. Data is expected in the second half of 2013. The company’s collaborators, the University of Southampton and ChronTech Pharma AB, continue their enrollment of patients in phase II studies of DNA vaccines for leukemia and hepatitis C virus, respectively, with interim data anticipated in the second half of 2012.

We expect to report data from two phase I influenza studies, one for our synthetic vaccine focused on H5N1 influenza, the other for our synthetic universal vaccine targeting H5N1 and H1N1, in the second quarter.

Preclinical Development

During the quarter we announced data from multiple research and preclinical programs.

Synthetic vaccines for influenza Type A H3N2 and Type B achieved protective antibody responses in immunized animals against multiple unmatched strains from the years 2000 through 2012, progressing our universal influenza vaccine strategy.

Inovio’s new skin electroporation technology significantly enhanced delivery of small interfering RNA (siRNA) molecules to skin and also demonstrated gene knockdown (silencing) in animal studies.

Inovio’s SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, associated with head & neck cancers and genital warts, induced strong antigen-specific CD8+ T cells in mice, mirroring robust T-cell responses induced by VGX-3100 in earlier mice studies.

Corporate & Business Development

Inovio received a patent covering its synthetic consensus influenza H1 antigen, which relates to our H1N1 influenza constructs and INO-3510 universal influenza vaccine.

Inovio was awarded a U.S. Department of Defense Small Business Innovation Research Grant to advance a low-cost, non-invasive surface electroporation delivery device and test its utility in combination with Inovio synthetic vaccines against viruses with bioterrorism potential.

Niranjan Y. Sardesai, Ph.D., was promoted to Chief Operating Officer and is now responsible for corporate and business development in addition to overseeing research and development.

Dr. Anthony Ford-Hutchinson, recently retired from his role as Senior Vice President, Vaccines Research and Development at Merck, joined Inovio’s Scientific Advisory Board.

Dr. Adel Mahmoud was appointed to Inovio’s Board of Directors. He is a professor at Princeton University, was President, Merck Vaccines, from 1999 to 2005, and also served as Merck’s Chief Medical Advisor for Vaccines and Infectious Diseases.

Inovio has an expanding dialog with vaccine and biotechnology companies as well as non-governmental and government agencies with the goal of securing non-dilutive funding for its vaccine programs and potentially new collaborations and partnerships to advance the development and commercialization of its SynCon® vaccine platform and specific SynCon vaccines.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio’s proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio’s clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended March 31, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

                                                          INOVIO PHARMACEUTICALS, INC.
                                                     CONDENSED CONSOLIDATED BALANCE SHEETS

                                                                                                                                             March 31,  December 31,
                                                                                                                                                2012           2011
                                                                                                                                                ----           ----
                                                                                                                                             (Unaudited)
                                                                     ASSETS
    Current assets:
    Cash and cash equivalents                                                                                                                $11,128,895    $17,350,116
    Short-term investments                                                                                                                   13,730,072     12,863,420
    Accounts receivable                                                                                                                      876,730        467,909
    Accounts receivable from affiliated entity                                                                                                39,066         38,406
    Prepaid expenses and other current assets                                                                                                760,733        746,049
    Prepaid expenses and other current assets
     from affiliated entity                                                                                                                  400,890        441,186
                                                                                                                                             -------        -------

    Total current assets                                                                                                                     26,936,386     31,907,086
    Restricted cash                                                                                                                          100,146        100,059
    Fixed assets, net                                                                                                                        355,302        295,785
    Intangible assets, net                                                                                                                   8,849,869      9,310,485
    Goodwill                                                                                                                                 10,113,371     10,113,371
    Investment in affiliated entity                                                                                                          8,509,969      9,071,513
    Investment in common stock warrants                                                                                                      294,000        100,000
    Other assets                                                                                                                             191,913        208,262
                                                                                                                                             -------        -------

    Total assets                                                                                                                             $55,350,956    $61,106,561
                                                                                                                                             ===========    ===========

                                                      LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
    Accounts payable and accrued expenses                                                                                                    $3,316,787     $4,318,942
    Accounts payable and accrued expenses due to
     affiliated entity                                                                                                                        82,158         20,344
    Accrued clinical trial expenses                                                                                                          773,769      1,059,372
    Common stock warrants                                                                                                                    8,417,492      5,176,319
    Deferred revenue                                                                                                                          48,739         79,502
    Deferred revenue from affiliated entity                                                                                                  376,042        388,542
                                                                                                                                             -------        -------

    Total current liabilities                                                                                                                13,014,987     11,043,021
    Deferred revenue, net of current portion                                                                                                  79,046         80,450
    Deferred revenue from affiliated entity, net
     of current portion                                                                                                                      1,867,944      1,961,694
    Deferred rent                                                                                                                             80,660         80,875
    Deferred tax liabilities                                                                                                                  78,859         78,859
                                                                                                                                              ------         ------

    Total liabilities                                                                                                                        15,121,496     13,244,899
                                                                                                                                             ----------     ----------
    Stockholders' equity:
    Inovio Pharmaceuticals, Inc. stockholders'
     equity:
    Common stock                                                                                                                             134,968        134,968
    Additional paid-in capital                                                                                                               257,838,611    257,235,707
    Accumulated deficit                                                                                                                      (218,346,123)  (210,091,174)
    Accumulated other comprehensive income                                                                                                    65,006         35,393
                                                                                                                                              ------         ------

    Total Inovio Pharmaceuticals, Inc.
     stockholders' equity                                                                                                                    39,692,462     47,314,894
    Non-controlling interest                                                                                                                 536,998        546,768
                                                                                                                                             -------        -------

    Total stockholders' equity                                                                                                               40,229,460     47,861,662
                                                                                                                                             ----------     ----------

    Total liabilities and stockholders' equity                                                                                               $55,350,956    $61,106,561
                                                                                                                                             ===========    ===========
                            INOVIO PHARMACEUTICALS, INC.
                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                    (Unaudited)

                                                                      Three Months Ended
                                                                           March 31,
                                                                           ---------
                                                                         2012               2011
                                                                         ----               ----
    Revenues:
    License fee and milestone
     revenue                                                          $24,838            $26,368
    License fee and milestone
     revenue from affiliated
     entity                                                           106,250             93,750
    Grants and miscellaneous
     revenue                                                        1,562,033          2,985,147
                                                                    ---------          ---------

    Total revenues                                                  1,693,121          3,105,265
    Operating expenses:
    Research and development                                        4,042,579          4,421,799
    General and administrative                                      2,488,088          3,319,232
    Gain on sale of assets                                           (651,000)          (250,000)
                                                                     --------           --------

    Total operating expenses                                        5,879,667          7,491,031
                                                                    ---------          ---------

    Loss from operations                                           (4,186,546)        (4,385,766)
    Other income (expense):
    Interest and other income, net                                     31,544              1,855
    Change in fair value of common
     stock warrants                                                (3,548,173)         2,331,868
    Loss on investment in
     affiliated entity                                              (561,544 )          (370,011)
                                                                    ---------           --------
    Net loss                                                       (8,264,719)        (2,422,054)
    Net loss attributable to non-
     controlling interest                                               9,770              9,441
                                                                        -----              -----
    Net loss attributable to
     Inovio Pharmaceuticals, Inc.                                 $(8,254,949)       $(2,412,613)
                                                                  ===========        ===========

    Loss per common share -basic
     and diluted:
    Net loss per share
     attributable to Inovio
     Pharmaceuticals, Inc.
     stockholders                                                      $(0.06)            $(0.02)
                                                                       ======             ======

    Weighted average number of
     common shares outstanding -
     basic and diluted                                            134,968,394        120,922,577
                                                                  ===========        ===========

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101
Media: Jeff Richardson, Richardson & Associates, 805-491-8313

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

SOURCE Inovio Pharmaceuticals, Inc.


Source: PR Newswire